CANCER

Research published on 16 October 2026 describes how activating the protein PPARD in immune cells may help them use fat more effectively and attack tumors. In laboratory experiments, the approach slowed or stopped the growth of several cancer types, including colorectal, breast, and ovarian cancers, as well as melanoma. The discovery could inform future immunotherapy development, but it has not yet established a safe or effective treatment for patients.

Researchers at Cold Spring Harbor Laboratory reported a potential strategy for improving immune responses against colorectal cancer. The research, published in Nature Immunology, suggests that a transcription factor normally associated with promoting cancer growth may be harnessed to support cancer-fighting activity within the immune system. The findings could inform future treatment research, but they remain an experimental discovery rather than an established treatment for patients.

BioNTech announced on 13 October 2026 that its experimental mRNA-based cancer immunotherapy did not meet the primary endpoint of a mid-to-late-stage clinical trial involving patients with head and neck cancer. The result represents a setback for the company's efforts to expand mRNA technology beyond infectious diseases and into cancer treatment. It also highlights why promising early-stage results must be confirmed in larger clinical trials.

Oncologists at Sir Ganga Ram Hospital in Delhi have reported gastrointestinal cancer cases in patients as young as 15, prompting discussion about why these cancers are appearing in some younger people. The possible role of air pollution has been raised, but a direct causal relationship has not been established.

India's government is planning to cap trade margins on certain non-scheduled cancer medicines at 30%. The proposal could reduce maximum retail prices by as much as 70% for affected products and potentially save patients approximately ₹2,500 crore annually.

A new treatment combination involving tucatinib, trastuzumab and pertuzumab has received FDA approval for maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy.

A Phase 3 clinical trial found that adding Epkinly to standard treatment reduced the risk of disease progression or death by 51% among patients newly diagnosed with diffuse large B-cell lymphoma.

Results from the large CompassHER2-pCR trial have identified clinical and molecular factors associated with a complete pathological response in certain patients with stage II–III HER2-positive breast cancer following 12 weeks of a less intensive chemotherapy regimen combined with HER2-targeted medicines.

Cancer Research UK has announced the PROSPECT-UK study, designed to investigate the increasing occurrence of bowel cancer among people under 50. Researchers will examine diet, lifestyle and environmental factors.

A multi-centre clinical trial spanning 12,000 participants shows an 89% sensitivity rate in pinpointing stage-1 malignancies through specialized circulating microRNA signatures.

DEAR MAYO CLINIC: I've heard that many symptoms of gynecologic cancers can mimic menstrual or menopausal changes, such as bleeding and pelvic pain. What symptoms should never be ignored, and when do I know it's time to...